|Bid||0.00 x 1800|
|Ask||0.00 x 800|
|Day's Range||34.84 - 37.14|
|52 Week Range||26.10 - 129.09|
|Beta (5Y Monthly)||1.23|
|PE Ratio (TTM)||N/A|
|Earnings Date||Aug 03, 2022 - Aug 08, 2022|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||85.20|
Subscribe to Yahoo Finance Plus to view Fair Value for NTRA
Natera, Inc. (NASDAQ: NTRA), a global leader in cell-free DNA (cfDNA) testing, today announced the publication of a manuscript in a leading journal in the organ transplant space, Transplantation, validating the performance of a novel two-threshold algorithm for its Prospera™ test for the assessment of transplant rejection. Prospera incorporates the donor fraction and the estimated amount of donor-derived cfDNA (dd-cfDNA) when assessing active rejection. In the study, Natera's new method demonstr
Natera, Inc. ( NASDAQ:NTRA ) insiders who purchased shares in the last 12 months were richly rewarded last week. The...
Natera, Inc. (NASDAQ: NTRA), a global leader in cell-free DNA (cfDNA) testing, today announced that it has presented data on the clinical utility of the company's Prospera™ and Renasight™ tests in 14 sessions at the American Transplant Congress (ATC) 2022 meeting. This expands on the thirteen peer-reviewed papers that have been published over the last twelve months, demonstrating the strong performance of both assays.